Skip to main content
Clinical Trials/NCT03270995
NCT03270995
Completed
Not Applicable

Efficacy of a Cognitive-existential Intervention to Address Fear of Recurrence in Women With Cancer: a Randomized Controlled Clinical Trial

McGill University3 sites in 1 country144 target enrollmentOctober 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Neoplasms
Sponsor
McGill University
Enrollment
144
Locations
3
Primary Endpoint
Fear of cancer recurrence inventory
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Studies show that cancer survivors have unmet needs, the most frequently cited being fear of recurrence (FCR). Moderate to high levels of FCR have been reported by as much as 49% of cancer patients and are more prevalent among women. FCR is associated with psychological distress, lower quality of life, and increased health care utilization. Little evidence exists that these problems are being addressed by current medical management.

Detailed Description

The present study aims to further test this cognitive-existential group intervention for FCR in a randomized control clinical trial with women with breast or gynecological cancer. Participants will be recruited from Princess Margaret Hospital, Mount Sinai Hospital, the Jewish General Hospital, and the Ottawa Hospital. 144 cancer patients will be randomized to either receive the 6 week cognitive-existential group intervention or to a control group. The control group will also consist of six weekly sessions during which participants will discuss the challenges of living with a cancer diagnosis, but without a clear focus on FCR. Women randomized to participate in the study will a) be 18 years or older; b) have a first diagnosis of breast or gynecological cancer with stages between IIII; c) be disease free at the start of the group; d) gave clinical levels of fear of cancer recurrence; e) have clinical levels of distress; and f) have completed their cancer treatment.

Registry
clinicaltrials.gov
Start Date
October 2014
End Date
February 1, 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Christine Maheu

Principal Investigator

McGill University

Eligibility Criteria

Inclusion Criteria

  • first diagnosis of BC or GC with stages between I-III;
  • disease-free at the start of the group;
  • women aged 18 years or older;
  • completion of treatment, with the exception of adjuvant chemotherapy or hormonal replacement therapy

Exclusion Criteria

  • non-English speakers
  • previous cancer recurrence
  • enrolled in another group psychotherapy at the time of the start of the study or during the course of the 6 sessions
  • unresolved mental health disorder judged to be clinically contra-indicated and/or likely to affect the group work, based on disclosure by the potential participant or clinically identified by the group leader.

Outcomes

Primary Outcomes

Fear of cancer recurrence inventory

Time Frame: up to 12 months post-intervention follow-up

Fear of cancer recurrence will be measured using the Fear of Cancer Recurrence Inventory (FCRI). The FCRI is a 42-item questionnaire that includes a global score as well as seven sub-scales including triggers, severity, psychological distress, functional impairment, insight, reassurance, and coping strategies. A score of 13 or greater on the nine-item severity subscale (range 0-36) indicates clinical level of FCR \[55\]. The instrument has been shown to have adequate reliability and validity (construct validity; r=0.68 to 0.77; and reliability scores; α=0.95).

Secondary Outcomes

  • Perceived risk of cancer recurrence(Pre- two weeks prior to the intervention, Post-one week after the end of the intervention, and three (T3) and six months (T4) following the end of the intervention)
  • Uncertainty in Illness(Pre- two weeks prior to the intervention, Post-one week after the end of the intervention, and three (T3) and six months (T4) following the end of the intervention)
  • Cancer-specific distress(Pre- two weeks prior to the intervention, Post-one week after the end of the intervention, and three (T3) and six months (T4) following the end of the intervention)
  • Intolerance of uncertainty(Pre- two weeks prior to the intervention, Post-one week after the end of the intervention, and three (T3) and six months (T4) following the end of the intervention)

Study Sites (3)

Loading locations...

Similar Trials